



Biosimilars Overview – Humira

Key Clinical Information

- Biosimilars undergo comprehensive analytical, preclinical, and clinical studies to confirm similarity to Humira.
- FDA-approved biosimilars meet stringent regulatory standards for safety, efficacy, and immunogenicity.
- Biosimilars offer a lower-cost alternative without compromising therapeutic outcomes.

10 FDA Approved Humira Biosimilars

- **Abrilada** (adalimumab-afzb)
- **Amjevita** (Adalimumab-atto)
- **Cyltezo** (Adalimumab-adbm)
- **Hadlima** (adalimumab-bwwd)
- **Hulio** (adalimumab-fkjp)
- **Hyrimoz** (adalimumab-adaz)
- **Idacio** (adalimumab-aacf)
- **Simlandi** (adalimumab-ryvk)
- **Yuflyma** (adalimumab-aaty)
- **Yusimry** (adalimumab-aqvh)

Benefits and Clinical Considerations

- **Efficacy & Safety:** No clinically meaningful differences in efficacy, mechanism of action, or therapeutic use. Biosimilars demonstrated comparable safety profile with a low risk of immunogenic response.
- **Interchangeability:** Some biosimilars may have interchangeability status, meaning they can be substituted without prescriber intervention.
- **Cost Benefits:** Reduced cost compared to Humira, improving patient access and affordability.
- **Insurance & Reimbursement:** Many insurance plans are shifting toward biosimilars, potentially requiring a prior authorization for Humira.
- **Administration:** Humira biosimilars use the same subcutaneous injection route; some biosimilars contain citrate-free formulations for less pain.
- **Patient Counseling:** Address concerns about effectiveness, switching concerns, and administration differences.

Prescribing Guidance

- Confirm formulary coverage with payers.
- Educate patients on the equivalency of biosimilars.
- Monitor patient response similarly to Humira.
- Reinforce that biosimilars maintain the same safety and efficacy standards.

www.azcarenetwork.org